SIGA Technologies Q2 2026 Earnings Breakdown | Business and Finance News

SIGA Technologies delivered a strong Q2 2026 with $38 million in revenue, driven by U.S. Strategic National Stockpile orders and international sales, signaling its enduring role in global biodefense. The company wrapped up its 19C contract and is advancing talks on a new multiyear U.S. deal, while expanding internationally via a Hikma partnership in MENA and securing key deals in Asia and Europe. With FDA submission for post-exposure prophylaxis targeted for early 2027 and pediatric formulation trials expected by year-end, SIGA is doubling down on innovation and strategic partnerships to meet the persistent threat of biological outbreaks. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/bb1e331ae0e1290e